Welcome to our dedicated page for Intra-Cellular Therapies news (Ticker: $ITCI), a resource for investors and traders seeking the latest updates and insights on Intra-Cellular Therapies stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Intra-Cellular Therapies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Intra-Cellular Therapies's position in the market.
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) will participate in two investor conferences: 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024, and Bank of America Healthcare Conference 2024 on May 16, 2024. The webcasts will be available on the company's website.
Intra-Cellular Therapies reported strong financial results in Q1 2024 with CAPLYTA net product sales of $144.8 million, a 53% increase from the previous year. The company reiterated its 2024 net sales guidance at $645 - $675 million and announced positive Phase 3 results for lumateperone as an adjunctive therapy for major depressive disorder.
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) will host a conference call and webcast on May 7, 2024, to discuss the financial results for the first quarter of 2024. The company focuses on CNS disorder therapeutics. Participants can register online to join the call and access the webcast through the Investor Relations section on the company's website.
